Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Girentuximab I-124 - Heidelberg Pharma

Drug Profile

Girentuximab I-124 - Heidelberg Pharma

Alternative Names: 124-Iodine labeled monoclonal antibody G250; 124-Iodine labeled WX-G250; 124-Iodine-cG250; 124I-cG250; Redectane

Latest Information Update: 04 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wilex
  • Developer Heidelberg Pharma AG
  • Class Antibody diagnostics; Monoclonal antibodies
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Renal cell carcinoma

Most Recent Events

  • 20 Dec 2017 Wilex withdraws the phase III REDECT 2 trial prior to enrolment due to new sponsor for Renal cell carcinoma diagnosis in USA (IV) (NCT01762592)
  • 16 Jan 2017 Girentuximab I-124 licensed to Telix Pharmaceuticals worldwide
  • 25 Apr 2016 Girentuximab I-124 is available for licensing as of 25 Apr 2016. http://www.wilex.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top